Rare dis­ease biotech Rally­bio cuts 19 staffers and sheds part­nered pre­clin­i­cal pro­grams

Rally­bio is lay­ing off close to half of its em­ploy­ees and seek­ing “al­ter­na­tive op­tions” for its pre­clin­i­cal pro­grams as it gets ready to put the two lead can­di­dates in­to Phase II.

Fac­ing a harsh fund­ing en­vi­ron­ment, Rally­bio joins a wave of biotechs dou­bling down on their most ad­vanced as­sets and shed­ding the rest to save costs. In to­tal, it is cut­ting 19 em­ploy­ees, or 45% of the work­force.

In its case, the New Haven, CT-based biotech is bet­ting on a pair of po­ten­tial rare au­toim­mune dis­ease treat­ments: RLYB212, an an­ti-HPA-1a an­ti­body de­signed to pre­vent fe­tal and neona­tal al­loim­mune throm­bo­cy­tope­nia (FNAIT); and RLYB116, a once-week­ly, low vol­ume sub­cu­ta­neous­ly in­ject­ed C5 in­hibitor that will be test­ed for com­ple­ment-me­di­at­ed dis­eases. It ex­pects to start a mid-stage tri­al for RLYB212 in preg­nant women and come up with a de­vel­op­ment plan for RLYB116 at an op­ti­mized dose in the sec­ond half of the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA